Efficacy of a combined tool for stage I non‑small cell lung cancer against lymph node metastasis

Nakada,Takeo; Yabe,Mitsuo; Ohtsuka,Takashi

doi:10.3892/ol.2022.13452

Efficacy of a combined tool for stage I non‑small cell lung cancer against lymph node metastasis

Authors:
- Takeo Nakada
- Mitsuo Yabe
- Takashi Ohtsuka
View Affiliations

Affiliations: Department of Surgery, Division of Thoracic Surgery, The Jikei University School of Medicine, Tokyo 105‑8471, Japan
Published online on: August 9, 2022 https://doi.org/10.3892/ol.2022.13452
Article Number: 332
Copyright: © Nakada et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In patients with clinical stage I non‑small cell lung cancer (NSCLC), the prediction of occult lymph node metastasis (LNM) based on a combination of morphology using high‑resolution computed tomography (HRCT) and metabolism using positron emission tomography (PET)‑CT is unknown. The present study evaluated the use of predictive radiological tools, chest CT and PET‑CT, for occult LNM in patients with clinical stage I NSCLC. The records of patients who underwent lobectomy between July 2014 and November 2021 were retrospectively reviewed. The differences in clinicopathological parameters, including CT and PET, between the LNM and non‑LNM groups were assessed. Pure solid tumor was defined as a consolidation‑to‑tumor ratio of 1. The optimal cut‑off value for predictive radiological tools for LNM was assessed according to the area under the receiver operating characteristic (ROC) curve. The present study included 288 patients, of whom 39 (13.5%) had LNM; of these 38 (97.4%) were pure solid type. Larger consolidation size (CS), higher maximal standardized uptake (SUVmax) value and histological type were statistically associated with LNM (all P<0.05). The optimal cutoff values of CS and SUVmax for predicting LNM were 19 mm and 5.5 respectively, as assessed using the area under the ROC curve. The combination of CS ≥19 mm and SUVmax ≥5.5 demonstrated a markedly higher odds ratio (9.184; 95% CI, 4.345‑19.407) than each parameter individually. The minimum values of CS and SUVmax associated with LNM were 10 mm and 0.8 respectively. Pure solid formation and CS as morphology and SUVmax as metabolism were useful tools that complemented each other in predicting LNM. The combined method of evaluating SUVmax and CS may identify eligibility for LN dissection. However, considering the minimum values of CS and SUVmax in LNM, it cannot affirm the omission of LN dissection for cases that do not meet the combined criteria using HRCT and PET‑CT.

View Figures

View References

1	National Comprehensive Cancer Network®, . NCCN Clinical Practice Guideline in Oncology (NCCN Guideline^®) Non-small cell lung cancer. https://www2.tri-kobe.org/nccn/guideline/lung/englishJune 10–2019
2	Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al: The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
3	Kim H, Goo JM, Kim YT and Park CM: Consolidation-to-tumor ratio and tumor disappearance ratio are not independent prognostic factors for the patients with resected lung adenocarcinomas. Lung Cancer. 137:123–128. 2019. View Article : Google Scholar : PubMed/NCBI
4	Hattori A, Hirayama S, Matsunaga T, Hayashi T, Takamochi K, Oh S and Suzuki K: Distinct clinicopathologic characteristics and prognosis based on the presence of ground glass opacity component in clinical stage IA lung adenocarcinoma. J Thorac Oncol. 14:265–275. 2019. View Article : Google Scholar : PubMed/NCBI
5	Ye T, Deng L, Wang S, Xiang J, Zhang Y, Hu H, Sun Y, Li Y, Shen L, Xie L, et al: Lung adenocarcinomas manifesting as radiological part-solid nodules define a special clinical subtype. J Thorac Oncol. 14:617–627. 2019. View Article : Google Scholar : PubMed/NCBI
6	Miyoshi T, Aokage K, Katsumata S, Tane K, Ishii G and Tsuboi M: Ground-glass opacity is a strong prognosticator for pathologic stage IA lung adenocarcinoma. Ann Thorac Surg. 108:249–255. 2019. View Article : Google Scholar : PubMed/NCBI
7	Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Høgholm A, Larsen K, et al: Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 361:32–39. 2009. View Article : Google Scholar : PubMed/NCBI
8	The Japan Lung Cancer Society, . Japanese guideline for lung cancer treatment. https://www.haigan.gr.jp/guideline/2018/1/1/180101050100.htmlJune 10–2019
9	Shirai K, Abe T, Saitoh JI, Mizukami T, Irie D, Takakusagi Y, Shiba S, Okano N, Ebara T, Ohno T and Nakano T: Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy. Oncol Lett. 13:4420–4426. 2017. View Article : Google Scholar : PubMed/NCBI
10	Li L, Ren S, Zhang Y, Guan Y, Zhao J, Liu J, Wang Q, Chen G, Chen H, Xiang J and Fu X: Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: Potential value in the clinic. Lung Cancer. 81:213–217. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kaseda K, Asakura K, Kazama A and Ozawa Y: Risk factors for predicting occult lymph node metastasis in patients with clinical stage I non-small cell lung cancer staged by integrated fluorodeoxyglucose positron emission tomography/computed tomography. World J Surg. 40:2976–2983. 2016. View Article : Google Scholar : PubMed/NCBI
12	Nakada T and Kuroda H: Narrative review of optimal prognostic radiological tools using computed tomography for T1N0-staged non-small cell lung cancer. J Thorac Dis. 13:3171–3181. 2021. View Article : Google Scholar : PubMed/NCBI
13	Hishida T, Miyaoka E, Yokoi K, Tsuboi M, Asamura H, Kiura K, Takahashi K, Dosaka-Akita H, Kobayashi H, Date H, et al: Lobe-specific nodal dissection for clinical stage I and II NSCLC: Japanese multi-institutional retrospective study using a propensity score analysis. J Thorac Oncol. 11:1529–1537. 2016. View Article : Google Scholar : PubMed/NCBI
14	Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Aokage K, Saji H and Watanabe SI; Japan Clinical Oncology Group Lung Cancer Surgical Study Group, : Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 161:1469–1480. 2021. View Article : Google Scholar : PubMed/NCBI
15	Suzuki K, Watanabe SI, Wakabayashi M, Saji H, Aokage K, Moriya Y, Yoshino I, Tsuboi M, Nakamura S, Nakamura K, et al: A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg. 163:289–301.e2. 2022. View Article : Google Scholar : PubMed/NCBI
16	Hattori A, Matsunaga T, Takamochi K, Oh S and Suzuki K: Clinical significance of positron emission tomography in subcentimeter non-small cell lung cancer. Ann Thorac Surg. 103:1614–1620. 2017. View Article : Google Scholar : PubMed/NCBI
17	Kuroda H, Nakada T, Oya Y, Takahashi Y, Matsusita H and Sakakura N: Clinical adjustability of radiological tools in patients with surgically resected cT1N0-staged non-small-cell lung cancer from the long-term survival evaluation. J Thorac Dis. 12:6655–6662. 2020. View Article : Google Scholar : PubMed/NCBI
18	Kim H, Goo JM, Kim YT and Park CM: Validation of the eighth edition clinical T categorization system for clinical stage IA, resected lung adenocarcinomas: Prognostic implications of the ground-glass opacity component. J Thorac Oncol. 15:580–588. 2020. View Article : Google Scholar : PubMed/NCBI
19	Chiang XH, Hsu HH, Hsieh MS, Chang CH, Tsai TM, Liao HC, Tsou KC, Lin MW and Chen JS: Propensity-matched analysis comparing survival after sublobar resection and lobectomy for cT1N0 LUNG ADENOCARCINoma. Ann Surg Oncol. 27:703–715. 2020. View Article : Google Scholar : PubMed/NCBI
20	Su H, Dai C, She Y, Ren Y, Zhang L, Xie H, Xie D, Jiang G and Chen C: Which T descriptor is more predictive of recurrence after sublobar resection: Whole tumour size versus solid component size? Eur J Cardiothorac Surg. 54:1028–1036. 2018. View Article : Google Scholar : PubMed/NCBI
21	Hattori A, Matsunaga T, Takamochi K, Oh S and Suzuki K: Importance of ground glass opacity component in clinical stage IA radiologic invasive lung cancer. Ann Thorac Surg. 104:313–320. 2017. View Article : Google Scholar : PubMed/NCBI
22	Takenaka T, Yamazaki K, Miura N, Mori R and Takeo S: The prognostic impact of tumor volume in patients with clinical stage IA non-small cell lung cancer. J Thorac Oncol. 11:1074–1080. 2016. View Article : Google Scholar : PubMed/NCBI
23	Fu F, Zhang Y, Wen Z, Zheng D, Gao Z, Han H, Deng L, Wang S, Liu Q, Li Y, et al: Distinct prognostic factors in patients with stage I non-small cell lung cancer with radiologic part-solid or solid lesions. J Thorac Oncol. 14:2133–2142. 2019. View Article : Google Scholar : PubMed/NCBI
24	Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:44–285. 2011. View Article : Google Scholar
25	Hayashi H, Ashizawa K, Ogihara Y, Nishida A, Matsumoto K, Yamasaki N, Nagayasu T, Fukuda M, Honda S and Uetani M: Comparison between solid component size on thin-section CT and pathologic lymph node metastasis and local invasion in T1 lung adenocarcinoma. Jpn J Radiol. 35:109–115. 2017. View Article : Google Scholar : PubMed/NCBI
26	Sakakura N, Inaba Y, Yatabe Y, Mizuno T, Kuroda H, Yoshimura K and Sakao Y: Estimation of the pathological invasive size of pulmonary adenocarcinoma using high-resolution computed tomography of the chest: A consideration based on lung and mediastinal window settings. Lung Cancer. 95:51–56. 2016. View Article : Google Scholar : PubMed/NCBI
27	Taira N, Atsumi E, Nakachi S, Takamatsu R, Yohena T, Kawasaki H, Kawabata T and Yoshimi N: Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the ¹⁸F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer. Lung Cancer. 123:30–35. 2018. View Article : Google Scholar : PubMed/NCBI
28	Park HK, Jeon K, Koh WJ, Suh GY, Kim H, Kwon OJ, Chung MP, Lee KS, Shim YM, Han J and Um SW: Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology. 15:1179–1184. 2010. View Article : Google Scholar : PubMed/NCBI
29	Nambu A, Kato S, Sato Y, Okuwaki H, Nishikawa K, Saito A, Matsumoto K, Ichikawa T and Araki T: Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann Nucl Med. 23:269–275. 2009. View Article : Google Scholar : PubMed/NCBI